NEW YORK, Oct 2 (Reuters) - Amicus Therapeutics Inc shares plunged 33.4 percent to $5.66 in extended trade on Friday after the company said its Plicera treatment for Gaucher disease failed to meet its endpoint in a Phase 2 study and does not expect the treatment to advance into phase 3 development.
(Reporting by Chuck Mikolajczak) Keywords: MARKETS STOCKS AFTERTHEBELL (Charles.mikolajczak@thomsonreuters.com; +1 646 223 5234; Reuters Messaging:rm://Charles.mikolajczak.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
(Reporting by Chuck Mikolajczak) Keywords: MARKETS STOCKS AFTERTHEBELL (Charles.mikolajczak@thomsonreuters.com; +1 646 223 5234; Reuters Messaging:rm://Charles.mikolajczak.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
